Central Serous Chorioretinopathy
Conditions
Brief summary
To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone
Interventions
OTHERSubthreshold Micropulse Laser Treatment
Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Inclusion criteria
* Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months. * Foveal serous retinal detachment for at least 6 months. * Minimum age of 18 years old at the screening time * Reading and comprehension skills of informed consent
Exclusion criteria
* Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone * No diffuse retinal epitheliopathy * Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization * Not controlled glaucoma with eyedrops, or advanced glaucoma * Myopia or hypermetropia greater than 6 diopters * Opacities of dioptric media * Low quality of optical coherence tomography (OCT) and OCT-Angiography scans * Low quality images of Fluorescein angiography and indocyanine green angiography * No written consensus signed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vessel density changes | 12 and 24 months | Evaluation of changes in vessel density of choriocapillaris by optical coherence tomography (OCT) angiography before and after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Choroidal thickness | 12 and 24 months | Evaluation of changes in choroidal thickness before and after treatment. |
| Choroidal thickness and vessel density | 12 and 24 months | Correlation among changes in choroidal thickness and changes in vessel density of choriocapillary with best corrected visual acuity. |
| Metamorphopsia | 12 and 24 months | Evaluation of quantitative improvement of metamorphosia by M-CHARTS after treatment. |
| Metamorphopsia and BCVA | 12 and 24 months | Correlation between metamorphopsia and best corrected visual acuity (BCVA) |
| Qualitative analysis of retino-choroidal vascularization with identification of vascular pattern | 12 and 24 months | To qualitatively evaluate the vascular patterns using optical coherence tomography (OCT) - angiography and to verify if a particular one is associated with a greater response to subthreshold micropulse laser treatment. |
| Improvement in retinal function | 12 and 24 months | To evaluate the potential improvement in retinal function with mean retinal sensitivity and microperimetry. |
| Quality of life (QoL) | 12 and 24 months | Evaluation of correlation among quality of life parameters assessed by visual function questionnaire (VFQ), stress and relapses and visual acuity. |
| Ellipsoid zone and BCVA | 12 and 24 months | To evaluate the association between ellipsoid zone integrity on optical coherence tomography (OCT) B scan and best corrected visual acuity (BCVA) |
| Ellipsoid Zone Integrity | 12 and 24 months | Evaluation of ellipsoid zone integrity by optical coherence tomography (OCT) B scan. |
Countries
Italy
Contacts
Primary ContactMaria Cristina Savastano, MD, PhD
Outcome results
None listed